A lot of evidence from various clinical trials and reported cases confirmed blockade of PD-L1 can cause an efficient response in patients with advanced melanoma, lung cancer, renal cell carcinoma, and gastric cancer. This evidence concerns the gene CD274 and renal cell carcinoma.